A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2017
At a glance
- Drugs Cridanimod (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Xenetic Biosciences
- 15 Aug 2017 According to a Xenetic Biosciences media release, interim data from this study are expected before the end of 2018.
- 26 Jun 2017 According to a Xenetic Biosciences media release, patient dosing is expected to commence in third quarter of 2017.
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.